Curie.Bio

Curie.Bio embeds a full-stack drug-development team inside seed-stage therapeutics companies, acting as a hands-on operating partner rather than a board-level investor. The firm provides capital alongside in-house expertise in CMC, clinical trial design, and regulatory strategy. This model shifts the primary value proposition from financial allocation to operational de-risking of preclinical and early clinical assets.

Curie.Bio targets the seed stage for therapeutics companies, with the explicit goal of preparing each portfolio company for a Series A or equivalent next round of financing. The firm's engagement is built around a concentrated window of 18 to 24 months of operational lift to make the science fundable by larger institutional investors.

The firm has not publicly disclosed its partnership structure or investment committee. Altss research identifies no named principals, managing partners, or listed leadership team. Curie.Bio's website and available public materials reference a team of drug hunters and company builders but provide no individual biographies.

Curie.Bio operates as a hybrid: it provides seed capital like a venture firm but embeds operational teams like an incubator. Unlike most incubators, however, it does not originate the science internally — it backs external academic or entrepreneurial founders and layers on its cross-functional team to advance the program toward a financing milestone.

The firm has not publicly disclosed its portfolio companies, names of therapeutics programs, or a record of post-seed financing rounds closed by its companies. As of the latest Altss review cycle, no verifiable funding outcomes are attributable to Curie.Bio in the public domain.